NEUROTROPE, INC. (OTCMKTS:NTRPD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)
On April 11, 2017, the Compensation Committee of the Board of Directors (the Board) of Neurotrope, Inc. (the Company) approved the following grants of options to purchase shares of the Companys common stock, par value $0.0001 per share (the Common Stock): (i) to Dr. Susanne Wilke, Ph.D., the Companys Chief Executive Officer, an option to purchase 62,500 shares of Common Stock, (ii) to Dr. Daniel Alkon, M.D., the Companys President, an option to purchase 167,000 shares of Common Stock and (iii) to Mr. Robert Weinstein, the Companys Chief Financial Officer, an option to purchase 18,945 shares of Common Stock. Each option grant has an exercise price of $19.62, which is equal to the price at which the Common Stock closed on April 11, 2017, as reported by The NASDAQ Capital Market, and shall vest in equal quarterly installments over a three-year period beginning on the date of grant. Each option grant is subject to a stock option agreement to be entered into by and between the Company and the optionee evidencing the granting of the options. Each option grant remains subject to approval of the Neurotrope, Inc. 2017 Equity Incentive Plan (the Plan) by the Companys stockholders.
The option grants were made to the Plan, which was approved by the Board on March 9, 2017. Copies of the Plan and the form of stock option agreement thereto are attached as Exhibits 10.1 and 10.2, respectively, and are incorporated herein by reference. The foregoing summary of the Plan is qualified in its entirety by reference to the full text of the Plan.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description of Exhibits | |
| 10.1 | Neurotrope, Inc. 2017 Equity Incentive Plan. | |
| 10.2 | Form of Stock Option Agreement under the Neurotrope, Inc. 2017 Equity Incentive Plan. |
About NEUROTROPE, INC. (OTCMKTS:NTRPD)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD. NEUROTROPE, INC. (OTCMKTS:NTRPD) Recent Trading Information
NEUROTROPE, INC. (OTCMKTS:NTRPD) closed its last trading session up +0.41 at 19.84 with 136,482 shares trading hands.
